Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects.

By W. James, I. Caterson, W. Coutinho, N. Finer, L. V. Van Gaal, A. Maggioni, C. Torp‐Pedersen, Arya M. Sharma, Gillian Shepherd, R. Rode and 1 more. New England Journal of Medicine, 2010

924 citations recorded by the source corpus.

Subfields: Emergency Medicine, Pharmacology, Surgery

View Paper: https://www.semanticscholar.org/paper/36fc5a681bd9f4665356c9d03d5466e65a2ee6ec

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. W. Garvey
2. David B. Allison
3. K. Gadde
4. C. Peterson
5. M. Schwiers
6. T. Najarian
7. P. Tam
8. B. Troupin

Citations in the corpus

• Real-world Evidence versus Randomized Controlled Trial: Clinical Research Based on Electronic Medical Records (2018, background): “25 The organization that conducts clinical research must bear the enormous consequences if the results of RCT research turn out to be different from those anticipated.”
• Controlled-Release Phentermine/Topiramate in Severely Obese Adults: A Randomized Controlled Trial (EQUIP) (2011, result): “By comparison, in the SCOUT Trial, the sibutramine treatment group exhibited a significantly increased heart rate combined with a significant elevation in BP compared with placebo (30).”